MedTrace Logo

Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

NCT00243204 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2007-06-08

No results posted yet for this study

Summary

This Phase 3 study will compare the efficacy of talabostat plus docetaxel to docetaxel plus placebo in patients with Stage IIIB/IV NSCLC who have failed a platinum-based chemotherapy regimen.

Conditions

  • Carcinoma, Non-Small Cell Lung

Interventions

DRUG

talabostat mesylate

DRUG

docetaxel

Sponsors & Collaborators

  • Point Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00243204 on ClinicalTrials.gov